Critical Contrast: Comera Life Sciences (NASDAQ:CMRA) versus AEON Biopharma (NASDAQ:AEON)

Volatility & Risk

Comera Life Sciences has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.

Valuation and Earnings

This table compares Comera Life Sciences and AEON Biopharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Comera Life Sciences	$1.00 million	0.00	-$18.00 million	N/A	N/A
AEON Biopharma	N/A	N/A	-$36.63 million	($6.08)	-0.14

Comera Life Sciences has higher revenue and earnings than AEON Biopharma.

Insider & Institutional Ownership

22.8% of AEON Biopharma shares are held by institutional investors. 8.9% of Comera Life Sciences shares are held by insiders. Comparatively, 0.9% of AEON Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Comera Life Sciences and AEON Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Comera Life Sciences	N/A	N/A	N/A
AEON Biopharma	N/A	N/A	-994.63%

Summary

Comera Life Sciences beats AEON Biopharma on 5 of the 6 factors compared between the two stocks.

About Comera Life Sciences

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

About AEON Biopharma

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.